Ortoma: Intervju hos Redeye om Ortomas nya globala samarbetsavtal

Publicerat 26 Sep, 2023

Ortoma har nyligen intervjuats av Redeyes analytiker Sebastian Andersson om det globala utvecklings- och distributionsavtal som Ortoma tecknade med en global aktör den 20 september 2023. Intervjun finns nu att ta del av på Ortomas hemsida.

Ortomas vd Linus Byström har nyligen besökt Redeye och blivit intervjuad om det nya globala samarbetsavtal Bolaget har tecknat avseende en kundanpassad version av Ortomas produkt OTS™. För att ta del av intervjun, besök Ortomas hemsida: https://ortoma.com/investor-relations/presentationer/

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.